Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Portobello SpA

    MCap

    EUR16m

    Last close

    EUR2.90

    ▲ 0.52 (21.85%)

    ArborGen Holdings

    MCap

    NZD77m

    Last close

    NZD0.15

    ▲ 0.01 (7.14%)

    ICL Group

    MCap

    USD5,729m

    Last close

    USD4.44

    ▲ 0.29 (6.99%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sareum Holdings: Edison Open House Healthcare 2022

Sareum Holdings: Edison Open House Healthcare 2022

Sareum Holdings — 2 videos in collection

More on this equity

Sareum Holdings is a UK-based drug development company, specialising in small molecule kinase inhibitors.

• Tell us about your business model and strategy for commercialisation.
• Why is there so much interest in JAK inhibitors?
• What is your strategy to progress SDC-1801 through clinical development after the first clinical trials in mid-2022? Are you actively assessing licensing/partnership opportunities?
• Are you planning to explore the recent positive data on SDC-1801’s immune-modulation properties in COVID-19?
• Might other respiratory diseases benefit from this?
• How has the CHK1 inhibitor that was out-licensed to Sierra Oncology progressed and how do you see it developing in the near to medium term?
• What is your cash runway? Where will the recent funding be directed and are you looking for more investment?
• Which milestones should investors focus on in the coming year?

< Previous
Next >

You may also be interested in these:

Healthcare

Sareum Holdings - Edison Open House interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free